Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Menopause. 2020 Aug;27(8):872–878. doi: 10.1097/GME.0000000000001557

Table 5.

Summary of total change in WMH volume and hormones levels adjusted for TIV

Total change oCEE tE2 Placebo Overall Pairwise P-value
(n = 23) (n = 24) (n = 31) P-value oCEE / Placebo tE2 / Placebo

WMH (cm3) 0.54 (0.60) 0.52 (0.77) 0.18 (0.28) 0.06* 0.12* 0.11*
FSH (IU/L) −23 (21) −33 (38) 7 (26) <0.001 0.001 <0.001
LH (IU/L) −6 (14) −13 (16) −3 (10) 0.04 0.81 0.04
E1 (pg/mL) 65 (60) 19 (22) −4 (22) <0.001 <0.001 0.07
E2 (pg/mL) 5 (15) 29 (39) −10 (34) <0.001 0.22 <0.001

Data are mean (SD)

Abbreviations; oCEE = oral conjugated equine estrogens, tE2 = transdermal estradiol, FSH = follicle stimulating hormone, LH = luteinizing hormone, E1 = estrone, E2 = estradiol, TIV = total intracranial volume, WMH = white matter hyperintensity

*

models adjusted for log-transformed TIV